


Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please amend claims 6, 7, 20 to 22 and 31 to 42 as shown.

1. (original): A compound of Formula I:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR_a, wherein R_a is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_a, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NSO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy;

R₂ is

hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

R₃ is

a direct link or
C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, C₁₋₆ hydroxyalkyl or C₁₋₆ carboxyalkyl; and

A₂ is


phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -N(R₁)COR_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, NHSO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d; or

-COR_c, -COOR_c or -CONR_cR_d, wherein

R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

2. (original): A compound of Formula II:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

R is

-COR_a, -CONR_aR_b, -SO₂R_a or -PO₃R_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;

A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c,

-COOR_c, -CONR_cR_d, -NHCOR_cR_d, -NHSO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d, wherein R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is
hydrogen, alkyl, hydroxy or alkoxy;

R₂ is
hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

R₃ is
a direct link or
C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, C₁₋₆ hydroxyalkyl or C₁₋₆ carboxyalkyl; and


A₂ is
phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -N(R₁)COR_e, -SO₂R_e, -SO₃R_e or -SO₂NR_eR_f;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -NHCOR_eR_f, NHSO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; or

-COR_e, -COOR_e or -CONR_eR_f, wherein

R_e and R_f are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

3. (original): A compound of Formula III:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR_a, wherein R_a is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;


A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_a, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NSO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy; and

R₂ is



wherein

R_c and R_d are independently hydrogen or alkyl;

X is N, O or S; and


A₂ is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -N(R₁)COR_e, -SO₂R_e, -SO₃R_e or -SO₂NR_eR_f; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -NHCOR_eR_f, NHSO₂R_e, -SO₂R_e, -SO₃R_e or -SO₂NR_eR_f, wherein

R_e and R_f are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

4. (original): A compound of Formula IV:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

R is

-COR_a, -CONR_aR_b, -SO₂R_a or -PO₃R_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;


A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, -HSO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d, wherein R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy; and

R₂ is



wherein

R_e and R_f are independently hydrogen or alkyl;

X is N, O or S; and

A_2 is


phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C_{1-4} alkyl, amino, aminoalkyl, halogen, hydroxy, $-CF_3$, alkoxy, aryloxy, arylalkoxy, $-OCF_3$, $-COR_g$, $-COOR_g$, $-CONR_gR_h$, $-N(R_1)COR_g$, $-SO_2R_g$, $-SO_3R_g$ or $-SO_2NR_gR_h$; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C_{1-6} alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, $-CF_3$, $-OCF_3$, $-COR_g$, $-COOR_g$, $-CONR_gR_h$, $-NHCOR_gR_h$, $NHSO_2R_g$, $-SO_2R_g$, $-SO_3R_g$ or $-SO_2NR_gR_h$, wherein

R_g and R_h are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

5. (original): A compound of claim 1, wherein

A_1 is




wherein R_a and R_b are independently -H, $-C_{1-6}$ alkyl, $-CO_2$ -alkyl or $-CO_2-CH_2CH_2NH_2$;

R₁ is -H;

R₂ is

-H, -Me, -Et,




wherein R_c is alkyl;

R₃ is

-CH₂-, -CH₂CH₂-, -CH(CH₃)-, -C(CH₃)₂-, -CH(CH₂OH)- or
-CH(CH₂CH₂COOH)-; and

A₂ is



wherein X is O or S.

6. (currently amended): A compound of Formula I according to claim 1, selected from
of claim 1, which is one of

4-(Benzothiazol-6-ylamino)-6-(ethyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(methyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(benzylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(methyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(ethyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-chloro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-fluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(pyridin-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2,6-difluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[methyl-(2-pyridin-2-yl-ethyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(pyridin-2-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(benzyl-(1-benzyl-pyrrolidin-3-yl)-amino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-fluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-chloro-6-methyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(N'-methyl-N'-phenyl-hydrazino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(pyridin-4-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-pyridin-3-yl-ethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-phenyl-propylamino)-[1,3,5]triazin-2-ol;

4-Benzothiazol-6-ylamino)-6-(2-pyridin-2-yl-ethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-naphthalen-1-yl-ethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-hydroxymethyl-phenylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(quinolin-5-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(4-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(1H-indazol-6-yl)-methylamino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(6-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-hydroxy-phenylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[2-(2-hydroxyethyl)-phenylamino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(5-thiophen-2-yl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol; 4-(Benzothiazol-6-ylamino)-6-(2-phenyl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2,4-difluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-phenylamino-[1,3,5]triazin-2-ol;
4-(1H-Indazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-hydroxy-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(1H-Indazol-5-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-7-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(furan-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(thiophen-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(furan-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(thiophen-3-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(benzyl-pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ol;
3-{{4-(Benzothiazol-6-ylamino)-6-hydroxy-[1,3,5]triazin-2-yl]-benzylamino}-propane-1,2-diol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-morpholin-4-ylpropyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-{benzyl-[3-(4-methyl-piperazin-1-yl)-propyl]-amino}-[1,3,5]triazin-2-ol;

4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-dimethylamino-propyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-piperazin-1-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-morpholin-4-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-dimethylamino-ethyl)-amino]-[1,3,5]triazin-2-ol; 4-(2-Amino-benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol; 4-(1-Methyl-1-phenylethylamino)-6-(quinolin-6-ylamino)-[1,3,5]triazin-2-ol;
4-(Quinolin-6-ylamino)-6-(N-ethylbenzylamino)-[1,3,5]triazin-2-ol;
4-(Quinolin-6-ylamino)-6-(N-methylbenzylamino)-[1,3,5]triazin-2-ol;
4-(Quinolin-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
N-[4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-yl]-hydroxylamine;
or a and pharmaceutically acceptable salt salts thereof.

7. (currently amended): A compound of Formula III according to claim 3, selected from ~~of claim 3, which is one of~~

4-(Benzothiazol-6-yl-amino)-6-(2-methyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-benzyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2,6-dimethyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2,5-dimethyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(3-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(3-methyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(morpholin-4-yl)-[1,3,5]triazine-2-ol;
or a and pharmaceutically acceptable salt salts thereof.

8. (original): A pharmaceutical composition, comprising a compound of any one of

claims 1 to 4 and a pharmaceutically acceptable carrier.

9. (original): A pharmaceutical composition, comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

10. (original): A pharmaceutical composition, comprising a compound of claim 6 or 7 and a pharmaceutically acceptable carrier.

11. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine; and
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

12. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of :

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and
- d) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-

(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)- [1,3,5]triazine, respectively.

13. (original): A method of claim 11 or 12, wherein the displaceable groups are chlorines.

14. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

- aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;
- bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and
- cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

15. (original): A method of preparing the compounds of Formulae I and III where R is -NHOH, comprising the steps of:

- aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;
- bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and
- cc) displacing the third displaceable group with hydroxylamine under acidic conditions to give a 4,6-diamino-([1,3,5]triazin-2-yl)-hydroxylamine.

16. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of:

- aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

- bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine;
- cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and
- dd) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)-[1,3,5]triazine, respectively.

17. (original): A method for inhibiting protein tyrosine kinase activity, comprising contacting the kinase with an effective inhibitory amount of at least one compound of any one of claims 1 to 4.

18. (original): A method for inhibiting protein tyrosine kinase activity, comprising contacting the kinase with an effective inhibitory amount of at least one compound of claim 5.

19. (original): A method for inhibiting protein tyrosine kinase activity, comprising contacting the kinase with an effective inhibitory amount of at least one compound of claim 6 or 7.

20. (currently amended): A method for inhibiting protein tyrosine kinase activity *in vitro* *in-vitro*, comprising contacting the kinase with at least one compound of any one of claims 1 to 4.

21. (currently amended): A method for inhibiting protein tyrosine kinase activity *in vitro* *in-vitro*, comprising contacting the kinase with at least one compound of claim 5.

22. (currently amended): A method for inhibiting protein tyrosine kinase activity *in vitro* *in-vitro*, comprising contacting the kinase with at least one compound of claim 6 or 7.

23. (original): A method for inhibiting protein tyrosine kinase activity in cells, comprising contacting the kinase with at least one compound of any one of claims 1 to 4.

24. (original): A method for inhibiting protein tyrosine kinase activity in cells, comprising contacting the kinase with at least one compound of claim 5.

25. (original): A method for inhibiting protein tyrosine kinase activity in cells, comprising contacting the kinase with at least one compound of claim 6 or 7.

26. (original): A method for inhibiting protein tyrosine kinase activity in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

27. (original): A method for inhibiting protein tyrosine kinase activity in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5.

28. (original): A method for inhibiting protein tyrosine kinase activity in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

29. (original): A method according to claim 17, wherein the protein tyrosine kinase is VEGFR-2 (KDR), c-fms or tie-2.

30. (original): A method according to claim 26, wherein the protein tyrosine kinase is VEGFR-2 (KDR), c-fms or tie-2.

31. (currently amended): A method of treating **tyrosine kinase mediated** cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

32. (currently amended): A method of treating **tyrosine kinase mediated** cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5.

33. (currently amended): A method of treating **tyrosine kinase mediated** cancer in a

mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

34. (currently amended): A method of treating **tyrosine kinase mediated** vascular diseases in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

35. (currently amended): A method of treating **tyrosine kinase mediated** vascular diseases in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5.

36. (currently amended): A method of treating **tyrosine kinase mediated** vascular diseases in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

37. (currently amended): A method of treating **tyrosine kinase mediated** ocular diseases in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

38. (currently amended): A method of treating **tyrosine kinase mediated** ocular diseases in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5.

39. (currently amended): A method of treating **tyrosine kinase mediated** ocular diseases in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

40. (currently amended): A method of treating **tyrosine kinase mediated** restenosis in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

41. (currently amended): A method of treating **tyrosine kinase mediated** restenosis in a mammal, comprising administering to the mammal a therapeutically effective amount of at least

one compound of claim 5.

42. (currently amended): A method of treating **tyrosine kinase mediated** restenosis in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

43. (original): A pharmaceutical dosage form comprising a pharmaceutically acceptable carrier and from about 0.5 mg to about 10 g of at least one compound of any one of claims 1 to 7.

44. (original): A dosage form according to claim 43 adapted for parenteral or oral administration.